Aurinia Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.11.24	Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis (Businesswire)
14.11.24	Aurinia to Participate in Jefferies London Healthcare Conference (Businesswire)
07.11.24	Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth (Businesswire)
30.10.24	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024 (Businesswire)
24.09.24	Aurinia Announces Approval Of LUPKYNIS In Japan - Quick Facts (RTTNews)
24.09.24	Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis (Businesswire)
13.09.24	Aurinia to Participate in 2024 Cantor Fitzgerald Global Healthcare Conference (Businesswire)
12.09.24	Aurinia Announces Board Restructuring (Businesswire)
05.09.24	Aurinia Announces First Participant Dosed in AUR200 Single Ascending Dose Trial (Businesswire)
28.08.24	Aurinia to Participate in H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
01.08.24	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results (Businesswire)
19.07.24	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 (Businesswire)
02.07.24	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Businesswire)
14.06.24	Aurinia Announces 2024 Annual General Meeting Results (Businesswire)
05.06.24	Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024 (Businesswire)
04.06.24	Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce (Businesswire)
04.06.24	Aurinia Provides Update on Proxy Statement (Businesswire)
30.05.24	Aurinia Will Attend 2024 Jefferies Global Healthcare Conference (Businesswire)
14.05.24	Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024 (Businesswire)
09.05.24	Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024 (Businesswire)
07.05.24	Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference (Businesswire)
02.05.24	Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results (Businesswire)
01.05.24	Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month (Businesswire)
30.04.24	The U.S. Food & Drug Administration (FDA) Approves Updated LUPKYNIS® (voclosporin) Label to include Long-Term Data from the AURORA Clinical Program (Businesswire)
15.04.24	Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024 (Businesswire)
09.04.24	Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor Conference (Businesswire)
29.02.24	Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program (Businesswire)
27.02.24	Aurinia to Participate in Upcoming Investor Healthcare Conferences (Businesswire)
15.02.24	Aurinia Discloses 2023 Year-End Financial and Operational Results, Announces Corporate Actions Focused on Enhancing Shareholder Value (Businesswire)
05.02.24	Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 (Businesswire)
05.01.24	Aurinia Provides Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue Results (Businesswire)
20.12.23	Aurinia Submits IND Application to US Food & Drug Administration for AUR 200 (Businesswire)
13.11.23	Aurinia Says Its Partner Otsuka Filed NDA For Voclosporin In Japan (RTTNews)
13.11.23	Aurinia Pharmaceuticals Announces Collaboration Partner Otsuka Filed New Drug Application (NDA) for LUPKYNIS® (Voclosporin) in Japan (Businesswire)
07.11.23	Aurinia Presents Breadth of Data from AURORA Clinical Program Underscoring Value of LUPKYNIS? (voclosporin) for Patients with Lupus Nephritis at ACR 2023 (Businesswire)
02.11.23	Aurinia Presents Breadth of Data at ASN 2023 Demonstrating Clinical Importance of LUPKYNIS? for Managing Lupus Nephritis (Businesswire)
02.11.23	Aurinia Pharmaceuticals Reports Third Quarter and Nine Months 2023 Financial and Operational Results (Businesswire)
26.10.23	Aurinia Response in Support of 2023 Updated EULAR Recommendations for Management of Lupus and New Treatment Paradigm for Lupus Nephritis (Businesswire)
19.10.23	Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 2, 2023 (Businesswire)
21.09.23	Aurinia Board of Directors Appoints Dr. Robert T. Foster as New Board Director And Enters Cooperation Agreement with Shareholder MKT Capital (Businesswire)
21.08.23	Aurinia Appoints Two New Board Directors with Deep Experience in BioPharma Leadership, Commercial Strategy, Mergers and Acquisitions and Advancing Therapeutic Pipelines (Businesswire)
03.08.23	Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results (Businesswire)
20.07.23	Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 3, 2023 (Businesswire)
30.06.23	Pre-market Movers: RNLX, BHG, PALT, ROOT, GHSI… (RTTNews)
30.06.23	Aurinia Pharma Gains 15% In Premarket As It Explores Strategic Options Including Sale (RTTNews)
29.06.23	Aurinia Board of Directors Announces Exploration of Strategic Alternatives to Maximize Shareholder Value (Businesswire)
20.06.23	Aurinia Showcases Three Oral Presentations for LUPKYNIS® (voclosporin) at 2023 European Renal Association Annual Meeting in Milan, Italy (Businesswire)
01.06.23	LUPKYNIS® (voclosporin) Achieved Significantly Higher Renal Response in Lupus Nephritis Patients with High Proteinuria Compared to Patients Treated with MMF and Low Dose Steroids Alone (Businesswire)
26.05.23	Aurinia Files Form S-8 to Register Shares Underlying Previously Disclosed Inducement Awards for Newly Hired Employees (Businesswire)
17.05.23	Aurinia Announces 2023 Annual General Meeting Results (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Alcon	77.62	1.81 %	K V
CieFinRichemont	122.35	0.99 %	K V
Lonza Grp	531.00	0.84 %	K V
Zurich Insur Gr	553.00	0.18 %	K V
Novartis	91.93	0.00 %	K V
ABB	49.54	-0.84 %	K V
Swisscom	504.00	-0.98 %	K V
Sika	228.60	-1.12 %	K V
Holcim	88.42	-1.51 %	K V
UBS Group	27.76	-2.08 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Aurinia Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten